Envenoming and antivenom use in Australia - PubMed
- ️Invalid Date
Envenoming and antivenom use in Australia
J White. Toxicon. 1998 Nov.
Abstract
Australia has a diverse and rich venomous fauna, both terrestrial and marine, including some of the most venomous species in each class. Antivenom is the principal therapy for the majority of medically significant envenomings and is currently supplied through a single source, CSL, Melbourne. Cases of envenoming reported to Australian poisons information centers (PICs) are dominated by spiderbite and insect stings, respectively accounting for 53.7% and 39.3% of all bite/sting calls. Marine animal bites/stings/poisonings account for only 4% of PIC calls in this category, while snakebites account for a mere 3% (still at least 400 calls/yr). Because most PIC calls are from the public, not doctors/hospitals, snakebite in particular is under-represented. The author has recently reviewed antivenom usage in Australia. Snakebite affects between 1,000 to 3,000 people per year, with an average annual mortality of about 2 cases. Brown snakes (genus Pseudonaja) cause the majority of deaths (and bites), with tiger snakes (genus Notechis) and taipans (genus Oxyuranus) accounting for nearly all other fatalities. Up to 500 cases require snake antivenoms each year, the majority of cases coming from rural areas of Queensland, Western Australia, New South Wales and Victoria, these being the most populated states. The wide availability of snake venom detection kits has allowed specific antivenom to be used more often, rather than polyvalent antivenom, but the latter is still used in nearly 30% of cases, suggesting underutilization of venom detection. The issue of premedication prior to antivenom remains unresolved. Antivenom usage and complication data for 1995 and 1996 will be presented. Red back spider antivenom is the most commonly used antivenom, with reports of usage being greater than for all other antivenoms combined. It is reported as being therapeutically efficacious in 94% of cases, with a single ampoule being used in 76% of cases, 2 ampoules in 18% of cases, and 3 or more ampoules in 6% of cases. Clinical experience suggests only 20% of red back spider bites require antivenom therapy. It is likely that between 5-10,000 bites occur annually.
Similar articles
-
Antivenom use in Australia. Premedication, adverse reactions and the use of venom detection kits.
Sutherland SK. Sutherland SK. Med J Aust. 1992 Dec 7-21;157(11-12):734-9. Med J Aust. 1992. PMID: 1360618
-
Bites and stings from venomous animals: a global overview.
White J. White J. Ther Drug Monit. 2000 Feb;22(1):65-8. doi: 10.1097/00007691-200002000-00014. Ther Drug Monit. 2000. PMID: 10688262 Review.
-
Allen GE, Brown SG, Buckley NA, O'Leary MA, Page CB, Currie BJ, White J, Isbister GK; ASP Investigators. Allen GE, et al. PLoS One. 2012;7(12):e53188. doi: 10.1371/journal.pone.0053188. Epub 2012 Dec 28. PLoS One. 2012. PMID: 23300888 Free PMC article.
-
The Australian Snakebite Project, 2005-2015 (ASP-20).
Johnston CI, Ryan NM, Page CB, Buckley NA, Brown SG, O'Leary MA, Isbister GK. Johnston CI, et al. Med J Aust. 2017 Aug 7;207(3):119-125. doi: 10.5694/mja17.00094. Med J Aust. 2017. PMID: 28764620
-
Innovative Immunization Strategies for Antivenom Development.
Bermúdez-Méndez E, Fuglsang-Madsen A, Føns S, Lomonte B, Gutiérrez JM, Laustsen AH. Bermúdez-Méndez E, et al. Toxins (Basel). 2018 Nov 2;10(11):452. doi: 10.3390/toxins10110452. Toxins (Basel). 2018. PMID: 30400220 Free PMC article. Review.
Cited by
-
Antivenom availability, delays and use in Australia.
Isbister GK. Isbister GK. Toxicon X. 2022 Dec 8;17:100145. doi: 10.1016/j.toxcx.2022.100145. eCollection 2023 Mar. Toxicon X. 2022. PMID: 36523639 Free PMC article.
-
Wickramaratna JC, Fry BG, Aguilar MI, Kini RM, Hodgson WC. Wickramaratna JC, et al. Br J Pharmacol. 2003 Jan;138(2):333-42. doi: 10.1038/sj.bjp.0705046. Br J Pharmacol. 2003. PMID: 12540524 Free PMC article.
-
Thalassophryne nattereri fish venom: from the envenoming to the understanding of the immune system.
Lopes-Ferreira M, Grund LZ, Lima C. Lopes-Ferreira M, et al. J Venom Anim Toxins Incl Trop Dis. 2014 Aug 13;20:35. doi: 10.1186/1678-9199-20-35. eCollection 2014. J Venom Anim Toxins Incl Trop Dis. 2014. PMID: 25140174 Free PMC article. Review.
-
A controlled clinical trial of a novel antivenom in patients envenomed by Bungarus multicinctus.
Ha TH, Höjer J, Trinh XK, Nguyen TD. Ha TH, et al. J Med Toxicol. 2010 Dec;6(4):393-7. doi: 10.1007/s13181-010-0051-4. J Med Toxicol. 2010. PMID: 20358414 Free PMC article. Clinical Trial.
-
The Snake Study: Survey of National Attitudes and Knowledge in Envenomation.
Braitberg G, Nimorakiotakis V, Yap CYL, Mukaro V, Welton R, Parker A, Knott J, Story D. Braitberg G, et al. Toxins (Basel). 2021 Jul 12;13(7):482. doi: 10.3390/toxins13070482. Toxins (Basel). 2021. PMID: 34357954 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials